Community Update: Novartis receives EMA CHMP positive opinion for Itvisma
Novartis receives EMA CHMP positive opinion for Itvisma, gene therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA).
On 23 April 2026, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Itvisma (intrathecal formulation of onasemnogene abeparvovec, developed by Novartis) for the treatment of adults and children aged 2 years and older living with spinal muscular atrophy (SMA).
For more information, click below.